Literature DB >> 21054563

Treatment of periorbital wrinkles with 1550- and 1565-nm Er:glass fractional photothermolysis lasers: a simultaneous split-face trial.

J Y Jung1, S B Cho, H J Chung, J-U Shin, K H Lee, K Y Chung.   

Abstract

OBJECTIVE: This study aimed to compare the clinical efficacies of 1550- and 1565-nm Er:glass lasers in the treatment of periorbital wrinkles and to evaluate histological changes after treatment.
METHODS: Twenty patients received five treatments each at 3-week intervals. The right periorbital area was exposed to the 1550-nm Er:glass laser and the left periorbital area was exposed to the 1565-nm Er:glass laser. Clinical improvement was evaluated by two blinded physicians who assessed comparative photographs using a four-point scale at baseline and 3 months after the final treatments. Skin biopsies were performed in five volunteers before treatment and at 3 months after the final treatment.
RESULTS: The mean improvement scores 3 months after treatment with the 1550- and 1565-nm Er:glass lasers were 2.25±0.62 and 2.28±0.59 respectively. Histological examination revealed increased epidermal thickening and decreased solar elastosis 3 months after the final laser treatments.
CONCLUSIONS: Both 1550- and 1565-nm Er:glass lasers are safe and effective modalities in the treatment of periorbital wrinkles with no significant differences between the two lasers.
© 2010 The Authors. Journal of the European Academy of Dermatology and Venereology © 2010 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21054563     DOI: 10.1111/j.1468-3083.2010.03870.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  1 in total

1.  Efficacy and safety of 1565-nm non-ablative fractional laser versus long-pulsed 1064-nm Nd:YAG laser in treating enlarged facial pores.

Authors:  Ying Wang; Yuxin Zheng; Suiqing Cai
Journal:  Lasers Med Sci       Date:  2022-08-15       Impact factor: 2.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.